mr. raab cite anticip declin sale
compani heart drug activas $ 185 million 1992
$ 195 million 1991. sale compani main
product dwarfism treatment protropin expect
grow less steepli past market becom
satur juvenil patient complet treatment
spokeswoman ad
nevertheless genentech said boost rate
research develop spend $ 260 million 50 %
revenu move product lab
clinic test 1992
